Travere Therapeutics Announces CEO Transition; Bradley Campbell Named CEO

What Happened

• Travere Therapeutics (TVTX) filed an 8-K on Sept. 21, 2026 announcing that President & CEO Eric Dube will step down effective December 1, 2026. Bradley L. Campbell will succeed him as President, CEO and board member effective December 1, 2026. Dr. Dube will serve as Executive Advisor through Feb. 15, 2027 and is expected to be engaged as a consultant for up to 18 months thereafter to support the transition.

Key Details

• CEO timing and transition: Eric Dube’s resignation effective Dec. 1, 2026; employment terminates no later than Feb. 16, 2027 (earlier if mutually agreed); Dr. Dube receives current base salary during transition and remains eligible for a 2026 bonus; 2027 bonus ineligible.
• New CEO pay and incentives: Bradley Campbell’s base salary $1,000,000; target annual discretionary bonus = 85% of base. He will receive an expense payment of $500,000 (with clawback provisions) and up to $10,000 for legal fees.
• Equity grants to Campbell: Initial equity awards valued at approximately $8,250,000 (non-qualified stock option) and $8,250,000 (time-based RSU), both vesting over four years; additional performance-based RSU ~ $3,750,000 to be granted in early 2027 tied to milestone achievement.
• Transition and severance protections: Dr. Dube may receive COBRA premium coverage up to 18 months if he elects COBRA; consulting and vesting protections (including acceleration in certain termination or change-in-control scenarios) are detailed. For Campbell, severance ranges include 1.5x (base + target bonus) if terminated without cause or for good reason (paid over 18 months), and 2.0x if termination occurs near a change in control; disability and death provisions also specified.

Why It Matters

• This is a material leadership change: a new CEO with extensive commercial and operational experience (former Amicus CEO) will guide Travere’s strategy and execution going forward. The structured transition and consulting arrangement aim to preserve continuity.
• Compensation and equity awards for the incoming CEO are significant and likely to affect near-term compensation expense and long-term dilution if fully realized; severance and acceleration clauses create additional potential costs in certain termination or change-in-control scenarios.
• Investors should note the filing’s forward-looking language and review the transition and employment agreements (filed as exhibits) for full terms and any potential impacts on governance, cash flow and equity outstanding.